Abstract Library

#4662 A novel hormone based anti-SSTR anti-CD3 T-cell engager for the treatment of neuroendocrine tumours

Introduction: Somatostatin receptor 2 (SSTR2) is overexpressed in well-differentiated NETs.

Conference:

Presenting Author: Pelle E

Authors: Pelle E, Cives M, Chaoul N, d'Angelo G, Medina E,

Keywords: T-cell engager, immunotherapy, tumouroids,

#4647 Crosstalk between cancer-associated fibroblasts and small intestinal neuroendocrine tumour cells in a 3D spheroid model

Introduction: At diagnosis, over 50% of small intestinal neuroendocrine tumours (SI-NETs) have metastasised to the mesentery where they often induce extensive fibrosis. Recent studies highlight the crucial interaction between SI-NET cells and cancer-associated fibroblasts (CAFs) in the pathogenesis of mesenteric fibrosis (MF).

Conference:

Presenting Author:

Authors: van der Slik E, Feelders R, van Koetsveld P, Iyer A, Hofland J,

Keywords: mesenteric fibrosis, small intestinal neuroendocrine tumour, CAF,

#4476 Pancreatic stellate cells promote tumorigenesis and progression of pancreatic neuroendocrine tumours through SERPINE2 and KCNA5

Introduction: Pancreatic stellate cells (PSC) are stromal cells in the pancreas that play a significant role in pancreatic pathology. Nevertheless, few studies have explored the significance of PSC in pancreatic neuroendocrine tumours (panNET). Their contribution to the fibrotic responses in panNET remains poorly understood. How PSC promote tumorigenesis and differentiation in panNET after being activated to myofibroblasts or cancer-associated fibroblasts (CAF) has not been studied.

Conference:

Presenting Author: Tang Q

Authors: Liu J, Li X, Bai J, Tang Q,

Keywords: caf, stellate cell, pan NET, Oncogenes,

#4428 Tumour-derived apolipoprotein E drives temozolomide chemoresistance by reprogramming lipid metabolism and activating the homologous recombination repair pathway in pancreatic neuroendocrine tumours

Introduction: Temozolomide (TMZ) is a first-class clinical drug for patients with pancreatic neuroendocrine tumours (pNETs). However, the therapeutic effects of TMZ are limited because of the chemoresistance of pNET cells.

Conference:

Presenting Author: Ji S

Authors: Lou X, Ji S, Xu X, Chen J, Yu X,

Keywords: Temozolomide, pancreatic neuroendocrine tumour, chemoresistance,

#4319 Everolimus combined with orlistat inhibits the development of neuroendocrine tumours by inhibiting the mTOR-PI3K-Akt signalling pathway

Introduction: Everolimus, an mTOR inhibitor, has demonstrated efficacy in NET treatment. Orlistat, used primarily for obesity management, inhibits fat absorption. This study investigates the potential synergistic effects of Everolimus combined with Orlistat on the development of NETs.

Conference:

Presenting Author:

Authors: Xu L, Tang Q, Ye M,

Keywords: Everolimus, orlistat, mTOR, PI3K/Akt, signalling pathway,